Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | MGTA-145 with plerixafor for the mobilization and collection of HSCs

John DiPersio • 3 Sep 2020
EBMT 2020
General MGTA-145 Plerixafor

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses the use of MGTA-145, a novel, rapid mobilizing agent also known as truncated GRO-beta along with plerixafor for the mobilization and collection of hematopoietic stem cells (HSCs). In primate models, this combination resulted in the rapid mobilization of stem cells sufficient for autologous stem cell transplant and therefore could eliminate the use of granulocyte-colony stimulating factor (G-CSF). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from John DiPersio

One big question with John DiPersio: what AML advance could transform frontline care in three years?
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
3:30
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
John DiPersio • 19 Sep 2025
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
1:14
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
John DiPersio • 19 Sep 2025
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
2:23
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
John DiPersio • 19 Sep 2025

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals